Composition, form of production and packaging
Lyophilizate for the preparation of eye drops in the form of a powder or a porous mass of white with a greenish shade of color.
1 f.
human superoxide dismutase recombinant 800,000 units
Solvent: water d / and.
Vials (1) in the set. with a solvent (amp 2 ml) and a pipette - packings of cellular contour (1) cassette - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2012.
PHARMACHOLOGIC EFFECT
Antioxidant drug. Superoxide dismutase is an endogenous acceptor of free oxygen radicals, the excessive accumulation of which in the cell plays an important role in the development of oxygen-dependent pathological processes (hypoxia, inflammation, intoxication). Superoxide dismutase catalyzes the reaction of the dismutation of superoxide radicals and prevents the formation of other radicals more dangerous to the body: hydroxyl radical and singlet oxygen.
Reksod В® -OF normalizes the oxidative processes taking place with the participation of free radicals of oxygen, incl. metabolic processes in nerve fibers. Prevents oxidative modification of proteins, stops the processes of atrophy of the optic nerve, as well as the destruction of cell membranes associated with the activation of lipid peroxidation.
PHARMACOKINETICS
1 hour after the administration, the therapeutic concentrations of the drug are present in the cornea and conjunctiva, as well as in the retina and optic nerve.
INDICATIONS
- primary open-angle glaucoma;
- Adenoviral lesion of the eyes;
secondary keratopathy.
DOSING MODE
Rexod В® -OF is instilled in the conjunctival sac. To prepare eye drops, the contents of the 0.8 million ED bottle are dissolved in 2 ml of water for injection. The resulting solution (eye drops) is stored in the refrigerator at a temperature of 4 В° to 10 В° C for not more than 3 days.
In the case of primary open-angle glaucoma , 2 drops are injected into the eye every 5 minutes for 30 minutes 2 times / day (morning and evening). The course of treatment is not less than 10 days. The course of treatment can be repeated after 1-3 months. The repetition of the course of treatment is necessary at the advanced and far advanced stages of the disease.
With secondary keratopathies : 2 drops 5-8 times / day; course - 3-7 days.
With adenovirus eye lesions: 2 drops 6-8 times / day with an interval of 1-2 hours; course of treatment - at least 10 days.
Local application of other ophthalmic drugs is possible no earlier than 10 minutes after instillation of the drug Reksod В® -OF.
SIDE EFFECT
Local reactions: there may be a feeling of dry eyes, redness, foreign body sensation that passes after the course of treatment; in some cases - allergic reactions.
CONTRAINDICATIONS
- age up to 18 years;
- Pregnancy;
lactation period (breastfeeding).
PREGNANCY AND LACTATION
Contraindicated in pregnancy and lactation (breastfeeding).
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
SPECIAL INSTRUCTIONS
The study of the drug Reksod В® -OF in patients wearing contact lenses was not carried out, therefore, during the treatment it is recommended to avoid wearing contact lenses.
Impact on the ability to drive vehicles and manage mechanisms
The drug does not affect the ability to drive vehicles.
OVERDOSE
The drug is not toxic. Cases of overdose are not known.
DRUG INTERACTION
Clinically significant interaction of the drug is not described.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children at a temperature of 4 В° to 10 В° C. Shelf life - 2 years.
